Edition:
United Kingdom

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

2.51EUR
15 Oct 2018
Change (% chg)

€-0.01 (-0.59%)
Prev Close
€2.53
Open
€2.52
Day's High
€2.56
Day's Low
€2.51
Volume
77,335
Avg. Vol
115,379
52-wk High
€4.83
52-wk Low
€2.44

Latest Key Developments (Source: Significant Developments)

MDxHealth Had Cash And Cash Equivalents Of $40.9 Million As Of June 30
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - MDXHEALTH SA ::H1 PRODUCT AND SERVICE REVENUE OF $16.6 MILLION, UP 39% FROM $12.0 MILLION IN H1 2017.SAYS H1 TOTAL REVENUE OF $17.2 MILLION, COMPARED TO NORMALIZED TOTAL REVENUE OF $12.2 MILLION DURING H1 2017.H1 GROSS PROFIT (EXCLUDING ROYALTIES) OF $10.0 MILLION IMPROVED BY 42% YEAR OVER YEAR.SAYS H1 OPERATING LOSS OF $15 MILLION IN H1 2018 COMPARED TO AN OPERATING PROFIT OF $0.6 MILLION IN H1 2017.CASH AND CASH EQUIVALENTS OF $40.9 MILLION AS OF JUNE 30.SAYS CLEAR GROWTH STRATEGY FOR REMAINDER OF 2018 AND BEYOND.  Full Article

Mdxhealth Says Palmetto Gba Issued A Positive Final Local Coverage Determination For ConfirmMDX
Monday, 23 Jul 2018 

July 23 (Reuters) - MDXHEALTH SA ::PALMETTO GBA ISSUED A POSITIVE FINAL LOCAL COVERAGE DETERMINATION (LCD) TO EXPAND MEDICARE COVERAGE OF CONFIRMMDX FOR PROSTATE CANCER TEST.FINAL LCD BECOMES EFFECTIVE ON SEPTEMBER 3, 2018.  Full Article

Mdxhealth Q1 Operating Loss widens to 6.7 Million Dollars
Tuesday, 24 Apr 2018 

April 24 (Reuters) - MDXHEALTH SA ::REG-MDXHEALTH PROVIDES FIRST QUARTER 2018.Q1 TOTAL REVENUE OF $9.7 MILLION, UP 50% FROM $6.5 MILLION IN Q1 2017.OPERATING LOSS OF $6.7 MILLION COMPARED TO $5.8 MILLION IN Q1 2017.Q1 PRODUCT REVENUE OF $7.9 MILLION, UP 60% FROM $4.9 MILLION IN Q1 2017.CASH AND CASH EQUIVALENTS OF $51.3 MILLION AS OF MARCH 31, 2018.DESPITE A STRONG Q1, WE DO NOT YET HAVE FULL VISIBILITY ON REVENUE PROJECTIONS GOING FORWARD - CEO.WE REMAIN CONFIDENT IN POSITIVE OUTLOOK FOR YEAR AND ACHIEVING HIGHER LEVELS OF TESTING VOLUME AND PRODUCT REVENUE COMPARED TO 2017 -CEO.  Full Article

Mdxhealth: Inclusion Of Selectmdx In Dutch Diagnosis Related Groups Reimbursement System
Friday, 20 Apr 2018 

April 20 (Reuters) - MDXHEALTH SA ::INCLUSION OF SELECTMDX FOR PROSTATE CANCER IN DUTCH DIAGNOSIS RELATED GROUPS (DRG) REIMBURSEMENT SYSTEM.  Full Article

Bookrunner On MDxHealth Books Says Accelerated Bookbuilding Of Offering Of Up To 9.9 Million
Wednesday, 21 Mar 2018 

March 21 (Reuters) - BOOKRUNNER::BLOCK TRADE : MDXHEALTH SA - BOOKRUNNER SAYS ACCELERATED BOOKBUILDING OF OFFERING OF UP TO 9.9 MILLION NEW SHARES OR UP TO ABOUT 20 PERCENT OF CURRENT SHARE CAPITAL.BLOCK TRADE : MDXHEALTH SA - BOOKRUNNER SAYS PRICE GUIDANCE OF OFFERING WITH REFERENCE TO MARKET‍​.  Full Article

MDxHealth Lowers Guidance For 2017
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - MDXHEALTH SA ::MDXHEALTH ANNOUNCES LOWERING OF 2017 GUIDANCE.WILL NOT MEET EARLIER GUIDANCE FOR REVENUE GROWTH IN 2017.ANTICIPATED AN INCREASE IN VOLUMES DURING Q4.HAS FACED TIMING ISSUES IN OBTAINING BILLABLE CASES FROM CONTRACTED CONFIRMMDX CUSTOMERS AND FROM POST-MARKETING STUDIES.DELAYED CONTRACTED CASES EXPECTED TO PARTLY SPILL OVER INTO 2018.EXPECTS TO FALL SHORT OF ITS YEAR-OVER-YEAR PRODUCT-AND SERVICES REVENUE GROWTH TARGET OF 45-55%, EXPECTING TO INSTEAD END YEAR AT GROWTH OF AROUND 10-15%.REVENUE EXPECTED TO GROW BY APPROX 32-37% COMPARED TO 2016.  Full Article

MDxHealth teams up with Ferrer for distribution of its prostate cancer test SelectMDx in Spain
Monday, 20 Nov 2017 

Nov 20 (Reuters) - MDXHEALTH SA : :REG-MDXHEALTH TEAMS UP WITH PHARMACEUTICAL COMPANY FERRER FOR DISTRIBUTION OF ITS PROSTATE CANCER TEST SELECTMDX IN SPAIN.‍UNDER TERMS OF THIS FIVE-YEAR EXCLUSIVE AGREEMENT, A TEAM OF 10 REPS FROM FERRER'S SALES FORCE OF ARE GOING TO SELL SELECTMDX TEST DIRECTLY TO 1000 UROLOGISTS IN SPAIN​.  Full Article

MDxHealth 9M total revenue at 30.5 million dollars
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - MDXHEALTH SA :9M (NOT Q3) NET LOSS $‍​7.4 MILLION VERSUS LOSS OF $10.3 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS ON SEPTEMBER 30, 2017 OF $22.9 MILLION.9M TOTAL REVENUE OF $30.5 MLN‍​.9M EBITDA IMPROVED BY 34.1% FROM $-6.2 MILLION COMPARED TO $-9.1 MILLION IN 2016‍​.TARGETS LOWER END OF ITS 55%-75% PRODUCT AND SERVICE REVENUE GROWTH GUIDANCE FOR 2017.2017 TOTAL REVENUE IS EXPECTED TO GROW BY APPROXIMATELY 60%-70%, TO $48-$51 MILLION.EXPECTS TO MAINTAIN A BALANCE OF CASH AND CASH EQUIVALENTS OF APPROXIMATELY $15 MILLION AT THE END OF 2017.  Full Article

MDxhealth enters distribution agreement with Unilabs for SelectMDx
Monday, 30 Oct 2017 

Oct 30 (Reuters) - MDXHEALTH SA ::‍MDXHEALTH ENTERS INTO DISTRIBUTION AGREEMENT WITH UNILABS FOR SELECTMDX FOR PROSTATE CANCER.​.  Full Article

MDxHealth and Queensland University of Technology collaborate on oral cancer liquid biopsy test
Monday, 19 Jun 2017 

June 19 (Reuters) - MDXHEALTH SA ::REG-MDXHEALTH AND QUEENSLAND UNIVERSITY OF TECHNOLOGY COLLABORATE ON ORAL CANCER LIQUID BIOPSY TEST.SIGNED SCIENTIFIC AGREEMENT WITH QUT BLUEBOX TO DEVELOP LIQUID BIOPSY EPIGENETIC ASSAY FOR EARLY DETECTION OF ORAL CANCER.  Full Article

BRIEF-MDxHealth Announces Positive Clinical Updates For ConfirmMDx

* REG-MDXHEALTH ANNOUNCES POSITIVE CLINICAL UPDATES FOR CONFIRMMDX